Multiple Sclerosis: Types, Diagnosis, and Disease-Modifying Therapies

One Million Americans, An Immune System Turned Against the Brain

Multiple sclerosis (MS) affects approximately 1 million people in the United States and 2.8 million worldwide — figures roughly doubled from previous estimates after a 2020 prevalence study used improved methodology. The disease strikes most often between ages 20 and 50, disproportionately affects women (3:1 female-to-male ratio in relapsing forms), and is the most common non-traumatic disabling neurological disease in young adults in the developed world. Despite its prevalence, MS remains poorly understood by the public: it is not always a wheelchair-bound diagnosis, its course is highly variable, and its treatment has been transformed over the past three decades.

MS is an autoimmune inflammatory disease of the central nervous system (CNS) in which the immune system attacks myelin — the protective fatty sheath surrounding nerve fibers — and, in progressive forms, the nerve fibers themselves. The resulting scarring (sclerosis) disrupts electrical signal conduction, producing the neurological symptoms characteristic of MS.

Demyelination: The Disease Mechanism

Myelin is produced by oligodendrocytes in the CNS and serves as both insulation and signal accelerator for nerve conduction. In MS, autoreactive T-cells — lymphocytes that mistakenly identify myelin proteins as foreign — breach the blood-brain barrier, triggering an inflammatory cascade. B-cells, macrophages, and cytokines join the attack, stripping myelin from axons in discrete areas called plaques or lesions. Early remission in relapsing MS often reflects remyelination and resolution of acute inflammation. Repeated attacks, however, exhaust oligodendrocyte precursors and leave permanent axonal damage — the substrate of progressive disability.

The locations of lesions in the brain and spinal cord determine the clinical presentation. Periventricular white matter, corpus callosum, optic nerves, brainstem, and spinal cord are preferentially affected. Lesion location explains MS's diverse symptom repertoire: optic neuritis (inflamed optic nerve), Lhermitte's sign (electric shock sensation on neck flexion from cervical spine lesion), vertigo, weakness, spasticity, bladder dysfunction, and cognitive impairment all reflect different lesion sites.

Four Clinical Subtypes

McDonald Criteria 2017: Diagnosing MS

The 2017 revision of the McDonald Criteria — the international diagnostic standard for MS — requires demonstration of "dissemination in space" (lesions in at least two distinct CNS locations) and "dissemination in time" (evidence that lesions occurred at different time points) or clinical evidence of a second attack. MRI has become the cornerstone of this process: T2/FLAIR sequences show hyperintense (white) lesions in characteristic locations, while gadolinium-enhancing lesions indicate active blood-brain barrier disruption in new lesions.

The 2017 criteria allowed MRI-based diagnosis without requiring a second clinical attack, reducing diagnostic delays. Key MRI criteria include periventricular lesions (≥3 lesions adjacent to ventricles), juxtacortical lesions, infratentorial lesions (brainstem/cerebellum), and spinal cord lesions. A single MRI showing both enhancing and non-enhancing lesions satisfies dissemination in time on one scan.

Cerebrospinal Fluid Analysis

Lumbar puncture (spinal tap) is not required for MS diagnosis when MRI criteria are met but provides supporting evidence in ambiguous cases. Oligoclonal bands (OCBs) — immunoglobulin bands present in CSF but not in serum — are found in 85–95% of people with MS, reflecting intrathecal immunoglobulin synthesis. Elevated IgG index and elevated myelin basic protein further support the diagnosis. CSF analysis is particularly valuable in excluding alternative diagnoses such as neuromyelitis optica spectrum disorder (NMOSD), which has different treatment implications.

Disease-Modifying Therapies: Efficacy and Risk

JC Virus and PML: Natalizumab's Defining Risk

Progressive multifocal leukoencephalopathy (PML) is a potentially fatal brain infection caused by reactivation of the JC virus (John Cunningham virus), a polyomavirus latent in approximately 50–60% of adults. In immunocompetent individuals, JC virus causes no clinical disease. In patients on natalizumab — which blocks lymphocyte trafficking into the CNS — the virus can reactivate and cause devastating opportunistic infection.

PML risk with natalizumab is stratified by three factors: anti-JC antibody status (positive vs. negative), antibody index (a measure of antibody titer), and treatment duration. Patients who are JC antibody-negative have a very low PML risk (~1 in 10,000). JC antibody-positive patients with an index above 1.5 and more than 24 months of natalizumab treatment face PML risk approaching 1 in 100 — a risk that requires individualized benefit-risk analysis. JC antibody testing every 6 months is standard practice for patients on natalizumab.

Fatigue Management in MS

Fatigue is the most common and often the most disabling MS symptom, reported by 75–95% of patients. MS fatigue is distinct from normal tiredness — it is a pervasive, disproportionate exhaustion that worsens with heat (Uhthoff's phenomenon) and does not consistently improve with rest. The mechanism involves both central fatigue (from neurological disruption of motor pathways) and secondary fatigue (from poor sleep, depression, deconditioning, and medication side effects).

Management approaches include:

• Cooling strategies (cooling vests, cold baths) to reduce heat-triggered fatigue
• Energy conservation techniques and occupational therapy
• Amantadine (100 mg twice daily) — modestly effective for central MS fatigue
• Modafinil — used off-label; clinical trial results are mixed
• Aerobic exercise programs — Level A evidence for fatigue reduction
• Cognitive behavioral therapy for fatigue-associated depression and maladaptive beliefs

The variability of MS — its unpredictable course, invisible symptoms, and highly individual treatment responses — makes it one of neurology's most challenging diseases to manage and one of the most misunderstood by employers, insurers, and the public alike. The treatment landscape is better than it has ever been, but the disease still wins too often.